 Compass Pathways plc NASDAQ: CMPS has announced results from Phase 2b trial of COMP360 psilocybin therapy for treatment-resistant depression. The study has achieved its primary endpoint for the highest dose, with a 25mg dose of COMP360 demonstrating a highly statistically significant and clinically relevant reduction in depressive symptom severity after three weeks, with rapid and durable treatment response. 